Published in Leukemia on March 19, 2009
Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol (2010) 9.35
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature (2010) 8.87
The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS One (2010) 8.10
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia (2009) 4.53
Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood (2011) 4.35
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia (2011) 4.28
Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev (2011) 4.09
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia (2010) 4.09
Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A (2011) 3.07
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol (2011) 3.01
CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood (2011) 2.52
The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell (2013) 2.33
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica (2009) 1.95
Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer (2010) 1.93
A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci U S A (2010) 1.81
Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc (2010) 1.63
Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood (2011) 1.59
Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol (2009) 1.42
Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics (2012) 1.29
Connections between TET proteins and aberrant DNA modification in cancer. Trends Genet (2014) 1.24
Hydroxylation of 5-methylcytosine by TET2 maintains the active state of the mammalian HOXA cluster. Nat Commun (2012) 1.21
TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunol Rev (2015) 1.18
Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis. Haematologica (2009) 1.16
Molecular basis of myelodysplastic/myeloproliferative neoplasms. Haematologica (2009) 1.14
Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes. Haematologica (2013) 1.13
TET proteins and the control of cytosine demethylation in cancer. Genome Med (2015) 1.13
The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia (2013) 1.11
Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells. Stem Cells Transl Med (2013) 1.09
Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis. Cell Rep (2013) 1.09
Playing TETris with DNA modifications. EMBO J (2014) 1.07
Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J (2016) 1.02
Molecular biology of myelodysplastic syndromes. Semin Oncol (2011) 1.01
Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. Haematologica (2010) 1.01
Driver mutations of cancer epigenomes. Protein Cell (2014) 0.98
Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J Clin Invest (2015) 0.96
Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F. Clin Cancer Res (2010) 0.95
TET family proteins: oxidation activity, interacting molecules, and functions in diseases. Chem Rev (2015) 0.94
Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups. Haematologica (2013) 0.91
Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Leuk Res (2010) 0.90
Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms. Am J Hematol (2010) 0.88
Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia. J Hematol Oncol (2014) 0.87
Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations. Haematologica (2013) 0.87
Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms. Hematol Oncol Clin North Am (2012) 0.86
ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One (2014) 0.85
TET2 plays an essential role in erythropoiesis by regulating lineage-specific genes via DNA oxidative demethylation in a zebrafish model. Mol Cell Biol (2014) 0.84
New answers to old questions from genome-wide maps of DNA methylation in hematopoietic cells. Exp Hematol (2014) 0.83
TET2 mutations in Ph-negative myeloproliferative neoplasms: identification of three novel mutations and relationship with clinical and laboratory findings. Biomed Res Int (2013) 0.82
A zebrafish model of myelodysplastic syndrome produced through tet2 genomic editing. Mol Cell Biol (2014) 0.81
Pathogenic microRNA's in myeloid malignancies. Front Genet (2014) 0.80
Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they? Haematologica (2012) 0.80
TET2 Expression in Bone Marrow Mononuclear Cells of Patients with Myelodysplastic Syndromes and Its Clinical Significances. Cancer Biol Med (2012) 0.80
TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia. Cancer Res (2015) 0.79
Chronic myelomonocytic leukemia: Forefront of the field in 2015. Crit Rev Oncol Hematol (2015) 0.78
The TET2 interactors and their links to hematological malignancies. IUBMB Life (2015) 0.78
The Impact of DNA Methylation in Hematopoietic Malignancies. Trends Cancer (2016) 0.78
Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance. Clin Epigenetics (2016) 0.77
JAK2V⁶¹⁷F/TET2 mutations: does the order matter? Haematologica (2011) 0.77
Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer J (2016) 0.77
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood Cancer J (2011) 0.77
JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg? Am J Hematol (2012) 0.77
Genetic Characterization of Ten-Eleven-Translocation Methylcytosine Dioxygenase Alterations in Human Glioma. J Cancer (2015) 0.77
Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms. F1000 Med Rep (2010) 0.76
The JAK2 gene as a protagonist in chronic myeloproliferative neoplasms. Rev Bras Hematol Hemoter (2013) 0.76
5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas. Sci Rep (2016) 0.76
Genomic profile of a patient with triple negative essential thrombocythemia, unresponsive to therapy: A case report and literature review. J Adv Res (2017) 0.75
Ten-Eleven Translocation-2 gene mutations: A potential new molecular marker in malignant gliomas (Review). Oncol Lett (2011) 0.75
Novel therapeutic strategies in myelodysplastic syndromes: do molecular genetics help? Curr Opin Hematol (2016) 0.75
Assessment of PET/CT in multifocal myeloid sarcomas with loss of TET2: a case report and literature review. Int J Clin Exp Pathol (2015) 0.75
Genome-scale technology driven advances to research into normal and malignant haematopoiesis. Scientifica (Cairo) (2012) 0.75
Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features. Oncotarget (2016) 0.75
TET2- and TDG-mediated changes are required for the acquisition of distinct histone modifications in divergent terminal differentiation of myeloid cells. Nucleic Acids Res (2017) 0.75
Adult T cell leukemia aggressivenness correlates with loss of both 5-hydroxymethylcytosine and TET2 expression. Oncotarget (2016) 0.75
Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis. J Clin Invest (2017) 0.75
Prognostic role of TET2 deficiency in myelodysplastic syndromes: A meta-analysis. Oncotarget (2017) 0.75
Epigenetics in Myeloproliferative Neoplasms. J Cell Mol Med (2017) 0.75
TET-mediated active DNA demethylation: mechanism, function and beyond. Nat Rev Genet (2017) 0.75
Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia (2007) 8.34
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia (2009) 4.53
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia (2009) 3.49
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia (2008) 3.04
Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol (1990) 8.97
Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet (1999) 6.61
Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell (1994) 4.64
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia (2009) 4.53
Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. N Engl J Med (1994) 4.46
Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids (2003) 3.66
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia (2009) 3.49
Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (1995) 3.38
Mutations and prognosis in primary myelofibrosis. Leukemia (2013) 3.13
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia (2008) 3.04
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet (2004) 2.96
Turnover of bacterial glutamine synthetase: oxidative inactivation precedes proteolysis. Proc Natl Acad Sci U S A (1981) 2.93
Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation (2009) 2.85
Oxidative damage during aging targets mitochondrial aconitase. Proc Natl Acad Sci U S A (1997) 2.76
Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood (1996) 2.73
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia (2010) 2.65
Critical care in the emergency department: a time-based study. Crit Care Med (1993) 2.59
Protein oxidation. Ann N Y Acad Sci (2000) 2.57
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia (2007) 2.49
Expression of interleukin 8 and CD54 by human gastric epithelium after Helicobacter pylori infection in vitro. Gastroenterology (1995) 2.48
Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut (2010) 2.47
Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell (2000) 2.41
FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res (2006) 2.41
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood (1997) 2.37
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia (2008) 2.35
Oxidative modification of glutamine synthetase. I. Inactivation is due to loss of one histidine residue. J Biol Chem (1983) 2.29
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia (2013) 2.25
Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation (2000) 2.22
PHF6 mutations in adult acute myeloid leukemia. Leukemia (2010) 2.20
Heart transplantation for end-stage heart failure due to cardiac sarcoidosis. Transplant Proc (2013) 2.15
Acute megakaryocytic leukemia (M7) in children. Mayo Clin Proc (1989) 2.13
Measurement of the intensity of cell surface antigen expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol (1994) 2.13
CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia (2013) 2.11
Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol (2001) 2.10
Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL. EMBO J (1997) 2.06
Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. J Exp Med (1990) 2.05
Glutamic and aminoadipic semialdehydes are the main carbonyl products of metal-catalyzed oxidation of proteins. Proc Natl Acad Sci U S A (2001) 2.04
Differential susceptibility of plasma proteins to oxidative modification: examination by western blot immunoassay. Free Radic Biol Med (1994) 2.03
The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci U S A (1996) 1.98
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia (2013) 1.97
Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia (2006) 1.95
The tongue flap in the primary treatment of cleft palate: a report of 19 cases. Br J Plast Surg (1992) 1.95
Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol (1996) 1.93
Development of an electrically stimulated neoanal sphincter. Lancet (1991) 1.91
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia (2011) 1.88
Clinical characteristics of paediatric H1N1 admissions in Birmingham, UK. Lancet (2009) 1.87
Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene (2011) 1.87
Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: a review. Am J Hematol (1998) 1.85
Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer (1997) 1.82
Mammalian thioredoxin reductase: oxidation of the C-terminal cysteine/selenocysteine active site forms a thioselenide, and replacement of selenium with sulfur markedly reduces catalytic activity. Proc Natl Acad Sci U S A (2000) 1.82
Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. J Biol Chem (2000) 1.82
True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases. Blood (1995) 1.81
Long-term use of anagrelide in young patients with essential thrombocythemia. Blood (2001) 1.81
Conversion of amino acid residues in proteins and amino acid homopolymers to carbonyl derivatives by metal-catalyzed oxidation reactions. J Biol Chem (1989) 1.80
DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia (2011) 1.79
Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia (2010) 1.79